This document discusses patient engagement in the health technology assessment (HTA) drug review process in Canada. It provides an overview of the different organizations involved in drug regulation and funding, and explains the value of incorporating patient input and perspectives into the HTA process. A key point is the Health Technology Assessment Patient Engagement Navigator (HTAPEN) project, which aims to promote and support patient involvement in HTA drug reviews through activities like workshops, online resources, and acting as a liaison between patient groups and the review process. The document outlines the goals and activities of the HTAPEN project in engaging patients in the assessment of new cancer drugs by regulatory bodies like CADTH's pCODR program.